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Abstract
Introduction: Neoadjuvant chemotherapy (CT) for locally 
advanced colon cancer (LACC) could potentially lead to tu-
mor shrinkage, eradication of micrometastases, and preven-
tion of tumor cell shedding during surgery. This retrospec-
tive study investigates the surgical and oncological out-
comes of preoperative CT for LACC. Methods: Using the 
Netherlands Cancer Registry, data of patients with stage II or 
III colon cancer, diagnosed between 2008 and 2016 was col-
lected. A propensity score matching (PSM; 1: 2) was per-
formed and compared patients with clinical tumor (cT) 4 co-
lon cancer who were treated with neoadjuvant CT to pa-
tients with cT4 colon cancer treated with adjuvant CT (Fig. 1). 
Results: A total of 192 patients treated with neoadjuvant CT 
were compared to 1,954 patients that received adjuvant CT. 
After PSM, 149 patients in the neoadjuvant group were com-
pared to 298 patients in the control group. No significant 
differences were found in baseline characteristics after PSM. 
After neoadjuvant CT, a significant response was observed 
in 13 (9%) patients with 5 (4%) patients showing a complete 
response. Complete resection margins (R0) were achieved in 
77% in the neoadjuvant group versus 86% in the adjuvant 
treated group (p = 0.037). Significantly less tumor positive 
lymph nodes were found in the neoadjuvant group (median 
0 vs. 2, p < 0.001). Major complication rates and 5-year over-
all survival did not differ between both groups (67–65%, p = 
0.87). Conclusion: Neoadjuvant CT seems safe and feasible 
with similar long-term survival compared to patients who 
are treated with adjuvant CT. © 2019 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Colorectal cancer is the third most common type of 
cancer worldwide [1]. With > 14,000 novel cases annually 
in the Netherlands, colorectal cancer can be held account-
able for approximately 5,000 cancer deaths a year. About 
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two-thirds of these patients present with colon cancer and 
approximately 15% of these patients present with locally 
advanced disease (i.e., T3 with ≥5 mm invasion beyond 
the muscularis propria or T4) without signs of distant 
metastases [2]. Current European guidelines recommend 
surgical resection of the primary tumor, followed by post-
operative chemotherapy (CT) in case of high-risk stage II 
or III tumors [3]. This recommendation has been dem-
onstrated to be effective in adenocarcinoma, but similar 
improved survival has recently been demonstrated in 
both mucinous and signet ring cell tumors [4, 5].
For locally advanced tumors located in the rectum, 
neoadjuvant chemoradiation is already well and widely 
established as the standard treatment protocol. Neoadju-
vant CT is thought to enhance tumor regression and 
downsizing of the tumor, which improves tumor resect-
ability and promotes higher rates of local control hence, 
achieve more R0 resections [6–9]. These benefits of neo-
adjuvant chemo (radio) therapy have also been proven 
for locally advanced breast cancer [10], gastric cancer 
[11], and esophageal cancer [12]. Another possible ad-
vantage of neoadjuvant therapy is the early eradication 
of systemic micrometastases, approximately 12 weeks 
earlier compared to CT administered postoperatively 
[13]. This could possibly prevent the occurrence of dis-
tant relapse and thus increase survival, particularly be-
cause resection of the primary tumor has shown to in-
duce growth factor activity, which enhances growth of 
micrometastases [14–18]. Moreover, in case of neoadju-
vant treatment, patients do not run the risk of suffering 
from postoperative complications which could lead to 
postponing or even omitting adjuvant CT. On the con-
trary, neoadjuvant CT does not always result in a re-
sponse, and disease progression could occur during 
treatment. Progression could lead to obstruction and the 
need for emergency surgery, which is associated with 
worse oncological outcomes with higher morbidity and 
mortality [19]. In a worst case scenario, patients cannot 
be treated with a resection of the primary tumor because 
of treatment-related toxicity or disease progression and 
inoperability.
There have been small series describing the feasibility 
of neoadjuvant CT or chemoradiation in colon cancer. 
These studies demonstrated safety, high percentages of 
R0 resections, and excellent local control rates [20–23]. 
The most striking evidence so far has been published by 
the foxtrot collaboration group. They published results 
from a pilot phase randomized clinical study comparing 
neo-adjuvant to adjuvant CT [21]. The preliminary out-
comes are promising but long-term outcomes are to be 
awaited and until now there is limited experience with 
this neo-adjuvant treatment strategy. 
The purpose of this population-based propensity-
score matched cohort study was to investigate the surgical 
and oncological outcomes of neoadjuvant CT for patients 
with locally advanced colon cancer (LACC). Surgical 
complications and pathological response to CT expressed 
as downstaging, mortality, and overall survival was com-
pared to patients with similar disease stage who received 
surgery followed by adjuvant CT.
Methods
Data Acquisition
Nationwide population-based data were acquired from the 
Netherlands Cancer Registry (NCR). This database contains every 
cancer diagnosis in the Netherlands since 1989 and has an esti-
mated completeness of at least 95%. The database is based on no-
tification by the nationwide automated pathology registry and the 
National Registry of Hospital Discharge Diagnosis. Trained data 
managers of the Netherlands Comprehensive Cancer Organiza-
tion obtain all data directly from patient medical files. Classifica-
tion of tumor characteristics was done according to the TNM Clas-
sification of Malignant Tumors [24] and International Classifica-
tion of Diseases for Oncology (ICD-O) [25]. To retrieve follow-up 
on vital status, the NCR is linked to the Municipal Personal Re-
cords database annually. At the time of data extraction, follow-up 
had been completed up to February 1, 2019.
Patient Selection
The database contained all patients who presented with either 
clinical or pathological stage II or III colon cancer (C18–C19) and 
who were treated with CT between 2008 and 2016. Follow-up data 
were available from the time of diagnosis until February 1, 2019. 
All patients with clinically CT-staged T4 colon cancer were select-
ed. Patients who received radiotherapy were excluded since these 
were mainly rectosigmoid tumors treated with neoadjuvant 
chemoradiation according to rectal cancer treatment protocols. 
Patients with tumor location coded as rectosigmoid were also ex-
cluded because it is not possible to determine if they were treated 
as rectal or sigmoid cancer based on the available information. 
 Patients who were not treated with surgical resection of the pri-
mary tumor were also excluded. LACC is defined as T4 or T3 with 
≥5 mm invasion beyond the muscularis propria but since the latter 
is not accurately distinguishable on CT, only patients with clini-
cally diagnosed clinical tumor (cT) 4 colon cancer were selected to 
represent locally advanced disease. Patients treated with neoadju-
vant CT followed by surgery (with or without adjuvant CT) were 
selected and compared to patients who underwent surgery fol-
lowed by adjuvant CT without any form of preoperative treatment 
(Fig. 1). 
Data Selection
The extracted data included the following variables: age, sex, 
localization of the tumor, differentiation grade, morphology, clin-
ical and pathological T and N stage, type of surgery, resection mar-
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gins, postoperative complications, length of follow-up, and vital 
status. Location of the tumor was coded according to the ICD-O 
(C18.0-C19.9) [8]. Morphology was divided into 3 subtypes: mu-
cinous (ICD-O 8480, 8481), signet ring cell (8490) and non-muci-
nous, non-signet ring cell adenocarcinoma (8000, 8010, 8020, 
8021, 8140, 8141, 8143, 8144, 8210, 8211, 8220, 8221, 8260, 8261, 
8262, 8263). Date of diagnosis was defined as the date of first his-
tological confirmation of malignancy, most often the day of endo-
scopic biopsy. After resection the pathologist performed final stag-
ing. Pathological tumor (ypT) and nodal staging was compared to 
clinical staging in both groups to assess downstaging effects of neo-
adjuvant CT and to highlight differences between clinical and ypT 
staging in the control group. R0 resections were achieved if the 
resection margins were microscopically free of tumor. In case of 
irradical resections, the resection was either labeled R1 (micro-
scopic involvement of the resection margins) or R2 (macroscopic 
involvement). Major postoperative complications were recorded 
(abscesses and/or anastomotic leakage). Thirty-day postoperative 
mortality was calculated for patients whose date of resection was 
known in the neoadjuvant group. Thirty-day mortality was not 
calculated in the adjuvant group because the control group only 
contains patients that were treated with adjuvant CT.
Data Analysis
First, patient and tumor characteristics were compared using 
the χ2 test. The Fisher’s exact test was used in case one or more if 
the expected outcomes were < 5. Continuous variables were de-
picted as mean + 95% CI or median + range and compared using 
independent sample t tests. p values < 0.05 were considered sig-
nificant. To assess the possibility of bias by baseline characteristics 
for neoadjuvant treatment, χ2 was performed. A propensity score 
matching (PSM) analysis including all baseline characteristics that 
were significantly associated with neoadjuvant CT treatment and 
all unbalanced baseline covariables was performed to adjust for 
confounding. Variables used in matching were: age, gender, year 
of diagnosis, tumor location, morphology, differentiation grade, 
clinical T-stage, and clinical N-stage. Patients were matched in a 
ratio of 1: 2 between the neoadjuvant and the control groups since 
this results in improved precision without an increase in bias [26]. 
All patients without a matching counterpart were excluded from 
the analyses. After PSM, baseline characteristics were compared to 
assure that no major differences persisted between the groups. Af-
ter PSM, OS curves were rendered according to the Kaplan-Meier 
method. The equality of the distribution between both groups was 
compared using the log-rank test. A landmark analysis was per-
formed to correct for immortal time bias. The landmark was set at 
the time point where 90% of both groups had started treatment. 
This cutoff point was determined to be 96 days. All patients with a 
follow-up of 95 days or less were excluded from the analysis. R0 
resection rates, postoperative complications, pT and pN stages 
were compared using χ2 tests. The number of harvested and posi-
tive lymph nodes was compared with independent sample t tests. 
Clinical and ypT and nodal staging were compared to evaluate the 
downstaging effects of neoadjuvant CT. Significant tumor down-
staging was defined as downstaging from cT4 to ypT2–0 and sig-
nificant nodal downstaging as cN+ to ypN0. In the control group, 
clinical and pathological nodal stagings were compared to assess 
under- and overstaging. For all statistical analyses, IBM SPSS Sta-
tistics software, version 25.0 (IBM Corporation, Armonk, NY, 
USA) was used. 
2,647 patient with clinically
stage T4 tumor
211 patients
treated with
radiotherapy
108 patients
with
rectosigmoid
cancer
Propensity score matching 1:2
– Age, gender, year of diagnosis
– Tumor location, morfology, differentiation
– cN and cT stage
The Netherlands cancer registry 2008–2016
– Nationwide database
– Retrospective cohort
182 patients
not treated
with surgery
2,146 T4 colon cancer patients
matching inclusion criteria
192 patients
neoadjuvant
149 patients
neoadjuvant
1,954 patients
adjuvantvs.
vs. 298 patientsadjuvant
16,177 patients with stage II or III
colon cancer who were treated with
a form of systemic CT
Fig. 1. Flowchart of patient selection. CT, 
chemotherapy; cT, clinical tumor.
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Results
Baseline Characteristics before Matching
From 2008 until 2016, 16,177 patients were diagnosed 
with stage II or III colon cancer and treated with CT. Only 
2,146 of these patients were diagnosed with cT4 colon 
cancer and matched the inclusion criteria. The majority 
of these (1,954 patients [91%]) were treated with surgery 
and adjuvant CT and 192 (9%) received neoadjuvant CT 
followed by surgery. The use of neoadjuvant CT treat-
ment increased significantly over time (p < 0.001; Fig. 2). 
In 2008, 4% of all patients diagnosed with a cT4 tumor 
were treated with neoadjuvant therapy compared to 
21.4% in 2016. Age was not significantly different be-
tween both groups, median age in the neoadjuvant group 
was 64 (range 29–84) vs. 64 years (range 25–88) in the 
control group, p = 0.9 (Table 1). Patients in the neoadju-
vant group had significantly more tumors located in the 
sigmoid colon (42 vs. 34%, p = 0.007) and significantly 
more T4b tumors (74 vs. 57.5%, p = < 0.001). 
Propensity Score Matching
A propensity score was calculated to adjust for biases 
caused by differences in baseline characteristics between 
the 2 groups. The propensity score was calculated based 
on: age (categories 0–50, 51–55, 56–60, 61–65, 66–70, 71–
75, 76–80, 80–> 80), gender, year of diagnosis, tumor lo-
cation, differentiation grade, morphology, clinical-T 
stage, and clinical-N stage. The PSM excluded 43 patients 
in the neoadjuvant group and 1,656 patients in the con-
trol group because no matching counterpart was found 
(with a match tolerance of 0.01). After matching there 
were no significant differences in baseline characteristics 
between both groups (Table 1).
Staging Accuracy in the Control Group
Comparison between clinical T stage and pathological 
stage shows that 105 (35%) patients with a T3 tumor and 
1 patient with a T2 tumor were overstaged as T4. Clinical 
nodal staging with CT detected lymph node metastases in 
119 (52%) of all 228 patients that were node-positive after 
pathological analysis. Seventy seven (34%) of these 228 
patients were understaged as cN0 and nodal status based 
on imaging was lacking in 32 (14%) of these 228 patients. 
Overstaging based on clinical imaging occurred in 16 
(23%) of all 68 patients that showed no evidence of nodal 
involvement after pathological assessment (Table 2b).
Downstaging
In patients treated with neoadjuvant CT, cT stage was 
compared to the ypT stage to investigate the effect of neo-
adjuvant CT on tumor load. 
In all patients, cT stage was reported before start of 
neoadjuvant CT. A total of 13 patients suggested signifi-
cant downstaging of the primary tumor after systemic 
therapy (cT4 to pT0–2, 8.7%). Five of these patients 
showed a complete pathological response (pT0; Table 3).
In the control group, only 1 clinically T4 staged tumor 
was overstaged as a pathological T2 stage (0.3%). This 
downstaging effect was statistically significant (p < 0.001).
Nodal downstaging was suggested in 34 of 65 patients 
who were clinically node-positive (52%; Table 2a). Nodal 
overstaging in the control group occurred only in 16 
(23%) patients that were diagnosed with cN+ even though 
they had pN0 disease. There were significantly less patho-
logically positive lymph nodes (median 0, range [0–23]) 
in the neoadjuvant group compared to the control group 
median 2 (0–23), (p = 0.01) The number of sampled 
lymph nodes was more than adequate in both groups, 
with a median of 17 (4–53) sampled nodes in the neoad-
juvant group and 20 (0–71) in the control group.
Surgical Outcomes
After matching the difference in incomplete resection, 
rates in favor of the adjuvant group remained significant. 
In 77.2% of patients (n = 115) in the neoadjuvant group, 
a complete resection (R0) was achieved. In 19 patients 
(12.8%), the resection margins were macroscopically free 
of disease but microscopically positive for tumor invasion 
(R1). In 6 patients (4%) it was not possible to achieve 
complete resection of the tumor and there was macro-
Fig. 2. Distribution of treatment regimen per year in percentage.
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scopically visible residual disease (R2). In the control 
group, an R0 resection rate of 86.2% (n = 225) was 
achieved. There were 6% (n = 18) R1 resections and 1.7% 
(n = 5) R2 resections. Data regarding complications was 
available in 92% of the patients (n = 137) in the neoadju-
vant group and in 93% (n = 275) of the control group 
(Table 3). There were no significant differences in surgi-
cal complications such as anastomotic leakage and ab-
scess formation between the 2 groups (p = 0.854).
Survival
The median follow-up was 44 (4–133) months in the 
neoadjuvant group and 44 (0–133) months in the control 
group. The 5-year overall survival was 67% in the neoad-
juvant group and 65% in the control group. However, this 
difference was not statistically significant (p = 0.867; 
Fig. 3). Thirty day mortality after surgery was 0% in the 
neoadjuvant group. This could not be compared to the 
control group because of immortal time bias. Multivari-
able Cox regression was not calculated since the Kaplan-
Meier curves crossed, and therefore the assumption of 
proportional hazards is violated. 
Discussion
Neoadjuvant CT for LACC is infrequently used and cur-
rent research is inconclusive regarding its potential benefit. 
With only a few studies published, it not surprising that 
neoadjuvant CT for LACCs is not considered a common 
practice in the Netherlands yet [21–23]. This nationwide 
database study illustrates that preoperative CT is safe, re-
sults in significant tumor and nodal downstaging and yields 
excellent long-term outcomes in a selected group of pa-
tients with clinically locally advanced (cT4) colon cancer.
Preoperative systemic therapy is shown to be non-in-
ferior in terms of safety and does not increase surgical 
morbidity or mortality when compared to standard sur-
Table 1. Baseline and tumor characteristics of neoadjuvant CT, compared to the locally advanced control group, raw and matched data
Raw data Propensity matched data
neoadjuvant CT + 
surgery (n = 192)
surgery + adjuvant 
CT (n = 1,954)
p value neoadjuvant CT + 
surgery (n = 149)
surgery + adjuvant 
CT (n = 298)
p value
Age, years, median (range) 64 (29–84) 64 (25–88) 0.905 66.0 66.0 0.662
Gender, n (%)
Male
Female
101 (52.6)
91 (47.4)
993 (50.8)
961 (49.2)
0.651 74 (49.7)
75 (50.3)
155 (52.0)
143 (48.0)
0.640
Localization, n (%)
Coecum
Colon
Sigmoid
31 (16.1)
80 (41.7)
81 (42.2)
503 (25.7)
772 (39.5)
679 (34.7)
0.007 28 (18.8)
64 (43.3)
57 (38.8)
63 (21.1)
129 (43.3)
106 (35.6)
0.808
Differentiation grade, n (%) 
Well/moderate
Poorl/undifferentiated
Unknown
72 (37.5)
26 (13.5)
94 (49.0)
1,231 (63.0)
540 (27.6)
183 (9.4)
0.432 71 (47.7)
26 (17.4)
52 (34.9)
141 (47.3)
49 (16.4)
108 (36.2)
0.945
Morphology, n (%)
Adenocarcinoma
Mucinous carcinoma
Signet ring cell carcinoma
Other/unknown
159 (82.8)
31 (16.1)
0 (0)
2 (1.0)
1,554 (79.5)
332 (17.0)
37 (1.9)
31 (1.6)
0.222 120 (80.5)
27 (18.1)
0 (0)
2 (1.3)
228 (76.5)
66 (22.1)
1 (0.3)
3 (1.0)
0.730
Clinical T-stage, n (%)
T4
T4a
T4b
19 (9.9)
31 (16.1)
142 (74.0)
397 (20.3)
433 (22.2)
1,124 (57.5)
<0.001 13 (8.7)
24 (16.1)
112 (75.2)
25 (8.4)
52 (17.4)
221 (74.2)
0.941
Clinical N-stage, n (%)
N0
N1
N2
Nx/unknown
81 (42.2)
63 (32.8)
23 (12.0)
25 (13.0)
721 (36.9)
633 (32.4)
193 (9.9)
407 (20.8)
0.061 65 (43.6)
47 (31.5)
18 (12.1)
19 (12.8)
120 (40.3)
84 (28.2)
51 (17.1)
43 (14.4)
0.483
Bold p values indicate statistical significance. 
CT, chemotherapy; T-stage, tumor stage; N-stage, nodal stage.
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gery. The occurrence of major complications such as 
anastomotic leakage and abscess formation was equal be-
tween both the groups. Patients in the neoadjuvant group 
were more likely to receive a stent or stoma prior to sur-
gery (8.7 vs. 1.0%) but far less likely to undergo emergen-
cy surgery compared to the control group (2.6 vs. 10.4%). 
These are encouraging results because they do not show 
evidence of tumor progression, warranting emergency 
resection during neoadjuvant treatment. This is in accor-
dance with the preliminary results of the Foxtrot trial 
where no differences in postoperative morbidity and 
mortality were observed between the 2 groups [21]. Re-
grettably, this dataset only contains patients that were 
treated with neoadjuvant treatment and surgery. Data re-
garding patients that received CT with neoadjuvant in-
tent but who were deemed inoperable because of tumor 
progression are lacking. On the contrary, in the Foxtrot 
trial all patients who were treated with neo-adjuvant CT 
underwent surgery and no mortality or progression lead-
ing to irresectable disease occurred in the pilot phase [21]. 
Another potential benefit of preoperative CT that was 
shown is significant downsizing of the primary tumor 
and downstaging of lymph nodes metastases. Evidence of 
significant downstaging was demonstrated in 13% of the 
patients and a complete pathological response was ob-
served in 5 patients. Also, an 18% reduction of lymph 
node involvement after preoperative treatment was ob-
served. These numbers might still be an underestimation 
of the effect since a significant number of patients were 
understaged in the control group. Neoadjuvant treatment 
has been proposed as a risk factor for inadequate lymph 
node sampling in rectal cancer and more recently in colon 
cancer [27, 28]. This was not observed in the present 
study as the median number of sampled lymph nodes was 
significantly higher than the recommended minimum of 
12 in both groups. 
Pathological and clinical staging were compared in the 
control group because there it is debated whether CT 
staging is an accurate tool to distinguish high-risk tumors 
suitable for neoadjuvant treatment. Significant tumor 
downsizing was defined as a reduction from cT4 to ypT2–
0 because distinction between T3 and T4 is difficult on 
CT, especially distinction between low-risk T1-T3ab and 
high-risk T3cd-T4 [29, 30]. This choice seems justified by 
the data that shows 35% of all clinically diagnosed T4 tu-
mors in the control group having a T3 tumor after patho-
logical assessment, suggesting significant overstaging. 
Conversely, the comparison of clinical and pathological 
nodal staging shows that the problem mostly lies in un-
derstaging with 35% of pN+ cases being diagnosed as 
clinically node-negative disease. This is in line with the 
recent literature on nodal staging in colorectal cancer 
[31]. This remains an important disadvantage of the neo-
adjuvant strategy because a significant number of pa-
tients could potentially receive neoadjuvant CT without 
appropriate indication. However, these data were collect-
ed over a longer period of time (2008–2016) and advanc-
es have been made in radiological staging T of colon can-
cer [32].
One of the hypothetical advantages of tumor downsiz-
ing and staging is a reduction of the amount of multivis-
ceral resections performed and a higher R0 resection rate. 
In this study this could not be demonstrated, since mul-
tivisceral resections were performed more often in the 
neoadjuvant group (9.4 vs. 5.0%) even though this differ-
ence was not significant. The rate and absolute number of 
patients who underwent a multivisceral resection is much 
lower compared to 33% multivisceral resections reported 
by Govindarajan et al. [33] in patients with LACC based 
on data retrieved from the SEER registry. The significant-
ly lower rate of R0 resections in the neoadjuvant group is 
a cause for concern since R0 resection strongly correlates 
with recurrence and survival in colorectal cancer [34, 35]. 
Nevertheless, this dataset contains no data regarding the 
presumed indication for neoadjuvant CT, rendering it 
highly difficult to determine if there is a causal relation-
ship between neoadjuvant treatment and the higher num-
ber of incomplete resections. There might be unknown 
Table 2.   
a Nodal downstaging in patients who received neoadjuvant CT
Pathological N-score
pN0 pN+ pNx Total
Clinical N-score
cN0 47 17 1 65
cN+ 34 31 0 65
cNx 11 8 0 19
Total 92 56 1 149
b Comparison of clinical and pathological nodal staging in pa-
tients treated with adjuvant CT
Clinical N-score
cN0 42 77 1 120
cN+ 16 119 0 135
cNx 10 32 1 43
Total 68 228 2 298
CT, chemotherapy.
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bias influencing the choice of neoadjuvant treatment. 
Since national guidelines recommend surgery in case of 
resectable tumors, presumably a significant percentage of 
patients treated with neoadjuvant CT had tumors with 
unfavorable characteristics and/or clinically unresectable 
tumors. This is supported by the finding that 28% of pa-
tients in the neoadjuvant group were treated with target-
ed therapy while treatment with the VEGF-A inhibitor 
Bevacizumab is normally reserved for palliative treat-
ment and not recommended in resectable disease [36]. 
Table 3. Surgical outcomes in patients treated with neoadjuvant CT, compared to the locally advanced control group, raw and matched data
Raw data Propensity matched data
neoadjuvant CT
(n = 192)
adjuvant CT
(n = 1,954)
p value neoadjuvant CT 
(n = 149)
adjuvant CT
(n = 298)
p value
Number of harvested lymph
nodes, mean(95% CI) 20.2 (18.8–21.6) 19.9 (19.5–20.4) 0.523 19.6 (18.1–21.2) 22.5 (21.2–22.0) 0.01
Number of positive lymph
nodes, mean (95% CI) 1.3 (0.9–1.7) 3.1 (3.0–3.3) <0.001 1.3 (0.8–1.8) 3.6 (3.1–4.1) <0.001
Pathological T-stages, n (%)
T0
T1
T2
T3
T4
Tx
8 (4.2)
2 (1.0)
8 (4.2)
70 (36.5)
104 (54.2)
0 (0)
0 (0)
0 (0)
12 (0.6)
734 (37.6)
1,207 (61.8)
1 (0.1)
<0.001 5 (3.4)
2 (1.3)
6 (4.0)
52 (34.9)
84 (56.4)
0
0 (0)
0 (0)
1 (0.3)
105 (35.2)
192 (64.4)
0
<0.001
Pathological N-stages, n (%)
N0
N1
N2
Nx
117 (60.9)
52 (27.1)
22 (11.5)
1 (0.5)
532 (27.2)
829 (42.4)
588 (30.1)
5 (0.3)
<0.001 92 (61.7)
38 (25.5)
18 (12.1)
1 (0.7)
68 (22.8)
121 (40.6)
107 (35.9)
2 (0.7)
<0.001
Resection margins, n (%)
R0
R1
R2
Unknown
150 (78.1)
24 (12.5)
7 (3.6)
11 (5.7)
1,681 (86.0)
100 (5.1)
55 (2.8)
118 (6.0)
0.001 115 (77.2)
19 (12.8)
6 (4.0)
9 (6.0)
225 (85.6)
18 (6.0)
5 (1.7)
20 (6.7)
0.037
Type of surgery, n (%)
Colon
Sigmoid
(Sub)total colon
Multivisceral resection
Unknown
100 (52.1)
66 (34.4)
7 (3.6)
18 (9.4)
1 (0.5)
1,175 (60.1)
592 (30.3)
55 (2.8)
120 (6.1)
12 (0.6)
0.187 82 (55.0)
47 (31.5)
5 (3.4)
14 (9.4)
1 (0.7)
172 (57.7)
95 (31.9)
14 (4.7)
15 (5.0)
2 (0.7)
0.485
Type of surgery, n (%)
Elective
Emergency
Previous stoma/stent
Unknown
171 (89.1)
5 (2.6)
16 (8.3)
0 (0)
1,727 (88,4)
203 (10.4)
17 (0.9)
7 (0.4)
<0.001 132 (88.6)
2 (2.6)
13 (8.7)
0
263 (88.3)
31 (10.4)
3 (1.0)
1 (0.3)
<0.001
Complication, n (%)
No anastomotic leakage or
abscess
Anastomotic leakage
Abscess
Both
Unknown
152 (79.2)
11 (5.7)
9 (4.7)
1 (0.5)
19 (9.9)
1,707 (87.4)
58 (3.0)
36 (1.8)
17 (0.9)
136 (7.0)
0.64 124 (83.2)
8 (5.4)
4 (2.7)
1 (0.7)
12 (8.1)
257 (86.2)
9 (3.0)
7 (2.3)
2 (0.7)
23 (7.7)
0.854
Targeted therapy, n (%)
Yes
No
54 (28.1)
138 (71.9)
33 (1.7)
1,921 (98.3)
<0.001 47 (31.5)
102 (68.5)
4 (1.3)
294 (98.7)
<0.001
Bold p values indicate statistical significance. 
CT, chemotherapy; T-stage, tumor stage; N-stage, nodal stage.
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The difference in R0 resections is, therefore, more likely 
a result of persisting bias based on unfavorable tumor 
characteristics and primary irresectability and not of the 
neoadjuvant treatment itself. This is supported by the 
preliminary data from the Foxtrot trial where in a ran-
domized setting the percentage of margin involvement is 
significantly lower in the neoadjuvant group (4 vs. 20%). 
An encouraging finding of this study is that despite the 
higher R0 resection rate, an excellent 5-year overall sur-
vival rate of 67% was demonstrated in the neoadjuvant 
group. This is similar to the survival in the control group 
(65%) and comparable to recent literature [37–39]. Most 
importantly, these results are in accordance with the first 
results of the randomized phase FOxTROT trial that were 
presented at the ASCO annual meeting 2019. The authors 
reported that there was no significant difference observed 
in the 2-year failure rate between both groups. Five-year 
overall survival results are required to confirm the long-
term benefits but the concordance with the results in this 
cohort is encouraging.
This study has some limitations; some degree of se-
lection bias is inevitable, owing to the observational na-
ture of the study. However, PSM was performed to bal-
ance the cohorts and differences in baseline characteris-
tics between the groups were no longer significant. 
Moreover, selection bias could have occurred in the 
control group since only patients who were able to un-
dergo adjuvant CT were included and as such patients 
who died postoperatively or suffered from severe com-
plications were excluded. Nevertheless, including these 
patients would introduce a form of bias benefitting the 
neoadjuvant group, since patients treated with neoadju-
vant intent but found to be not eligible for surgery are 
also not included in this study. It is encouraging that 
survival is still comparable between both groups, under-
lining the potential value of neoadjuvant treatment in 
this select group of patients. Unfortunately, the NCR 
does not contain data on disease recurrence and thus 
disease-free survival cannot be calculated. The overall 
survival percentages in both groups are comparable 
since tumor recurrence is significantly associated with 
overall survival [40]. Pathological data on tumor regres-
sion after neoadjuvant treatment are also absent and 
could be of interest since this is known to correlate with 
recurrence-free survival in other gastrointestinal malig-
nancies [41, 42]. Finally, the NCR does not contain spe-
cific data on the type of CT and whether patients suf-
fered treatment-related toxicity. However, the standard 
adjuvant treatment regimen for colon cancer in the 
Netherlands consists of a fluoropyrimidine and oxali-
platin combination and it is highly likely that neoadju-
vant treatment also consists of this combination.
In conclusion, this is the first nationwide population-
based analysis which shows that neoadjuvant CT for lo-
cally advanced cT4 colon cancer seems safe and yields 
similar overall survival compared to adjuvant CT. A low-
er R0 resection rate was observed in the neoadjuvant 
group but there is no significant increase in postoperative 
complications or mortality. Moreover, it leads to signifi-
cant downstaging of tumor and lymph node stage. The 
long-term survival benefit of this treatment is to be estab-
lished in a large randomized trial, but it already seems to 
be a useful and safe modality in patients with locally ad-
vanced and possibly unresectable primary tumors.
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Fig. 3. Landmarked overall survival after propensity matching.
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